News

Deal Announcements

Paratek Raises New Financing Of $22 Million

Friday, October 26, 2007 5:00:00 AM PDT | VentureDeal Staff
BOSTON, MA -- Paratek Pharmaceuticals, Inc. has raised an additional $22 million in new investment from a syndicate of venture capital firms.

Paratek is discovering and developing therapeutics to overcome the problem of bacterial resistance.  The company has developed two platforms, Tetracycline and Multiple Antibiotic Resistance, to combat, cure and prevent infectious diseases.

Investors in the round included lead investor Aisling Capital, the D.E. Shaw Group, Nomura Phase4 Ventures, Novartis BioVenture Fund, HBM Bioventures and Hercules Technology Growth Capital.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1